Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

Enzalutamide increases the amount of YOD1. 1 / 1

| 1

➶

reach

"However, there are few reports about the role of lncRNA in disease progression after enzalutamide resistance in PCa.In this study, we found that enzalutamide resistance induced by lncRNA NONHSAT210528 promoted the expression of YOD1 through the mechanism of competitive endogenous RNA (ceRNA) by regulating the expression of miR-21-5p in PCa cells after resistance to enzalutamide."

35693714

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...